RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GROHé C
Collezione AOU San Luigi di Orbassano

Items : 5

Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2023 May;179:107173. doi: 10.1016/j.lungcan.2023.03.009. Epub 2023 Mar 15.

2023
AOU San Luigi di Orbassano

Reck M; Popat S; Grohé C; Corral J; Novello S; Gottfried M; Brueckl W; Radonjic D; Kaiser R; Heymach J;

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 5.

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Scagliotti GV; Porcu L; Manegold C; Monica V; Wiest G; Irtelli L; Caffo O; Dickgreber NJ; Follador A; Pedrazzoli P; Bearz A; Griesinger F; Folprecht G; Schmid-Bindert G; Reck M; Chiari R; Gregorc V; Santo A; Morabito A; Schena M; Valmadre G; Borra G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Apr;33(4):454. doi: 10.1016/j.annonc.2022.01.005. Epub 2022 Jan 25.

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Porcu L; Manegold C; Scagliotti GV; Monica V; Wiest G; Irtelli L; Dickgreber NJ; Caffo O; Pedrazzoli P; Bearz A; Folprecht G; Griesinger F; Follador A; Chiari R; Reck M; Morabito A; Santo A; Schmid-Bindert G; Gregorc V; Schena M; Valmadre G; Borra G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2020 Jun;144:76-84. doi: 10.1016/j.lungcan.2020.04.009. Epub 2020 Apr 20.

2020
AOU San Luigi di Orbassano

Popat S; Grohé C; Corral J; Reck M; Novello S; Gottfried M; Radonjic D; Kaiser R;

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2017 Dec;18(12):1652-1664. doi: 10.1016/S1470-2045(17)30681-2. Epub 2017 Oct 23.

2017
AOU San Luigi di Orbassano

Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E;